EarningsDanaher posted top-line and bottom-line results ahead of Street models, with Biotech and Diagnostics segments showing strong performance.
Market DynamicsBioprocess market dynamics improved as customers returned to normal consumables ordering patterns, indicating a healthy market demand.
Share BuybackDanaher resumed a material share buyback, reducing its share count significantly, which supports the view of a solid bioprocess recovery.